Awakn Life Sciences Announces Credit Facility Dec 18, 2024 08:30AM
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc Dec 16, 2024 08:30AM
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program Dec 10, 2024 05:30PM
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites Oct 22, 2024 07:30AM
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program Oct 15, 2024 07:30AM
View Older Stories

Oct 4, 2024 07:30AM Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Sep 18, 2024 07:30AM Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Aug 28, 2024 07:30AM Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Aug 9, 2024 07:30AM Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Jul 31, 2024 07:30AM Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
Jul 22, 2024 05:00PM Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
Jul 18, 2024 07:30AM Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC
Jun 4, 2024 07:30AM Awakn Life Sciences Announces Closing of Tranche of Private Placement
May 2, 2024 06:00PM Awakn Life Sciences Discusses Filing of Financial Statements
Apr 17, 2024 07:30AM Awakn Life Sciences Announces Closing of Tranche of Private Placement
Apr 3, 2024 07:30AM Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
Feb 12, 2024 07:30AM Awakn Life Sciences Announces Listing on the Canadian Securities Exchange
Feb 5, 2024 07:30AM Awakn Life Sciences Announces Conditional Approval of CSE Listing
Jan 24, 2024 07:30AM Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
Dec 20, 2023 07:30AM Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
Dec 15, 2023 07:30AM Awakn Life Sciences Provides Corporate Update
Nov 15, 2023 07:30AM Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
Nov 10, 2023 05:00PM Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
Oct 31, 2023 07:30AM Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder
Oct 4, 2023 08:30AM Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study
Sep 14, 2023 07:30AM Awakn Life Sciences Provides Corporate Update
Sep 6, 2023 07:30AM Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001
Aug 1, 2023 07:30AM Awakn Life Sciences Completes Sale of Awakn Clinics In Norway
Jul 5, 2023 07:30AM Awakn Life Sciences Completes Sale of Awakn Clinics London
Jun 27, 2023 05:00PM Awakn Life Sciences Announces Results of Annual General and Special Meeting
Jun 19, 2023 07:30AM Awakn Life Sciences to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
Jun 15, 2023 07:30AM Awakn Life Sciences Announces Closing of the Second Tranche and Upsizing of Previously Announced Private Placement
Jun 9, 2023 12:00PM Awakn Life Sciences to Focus Solely on Research and Development of Therapeutics Targeting Addiction
Apr 28, 2023 07:30AM Awakn Life Sciences Reports Q4 2023 and Annual Results
Apr 26, 2023 08:18AM Awakn Life Sciences Announces Private Placement
Apr 18, 2023 07:30AM Awakn Life Sciences Signs Collaboration Agreement with University of Exeter for Upcoming Phase III Trial
Apr 12, 2023 07:30AM Awakn Life Sciences Increases Ownership of Awakn Bristol to 100% and Provides Corporate Update
Feb 28, 2023 07:30AM Awakn Life Sciences Signs Its Fourth Licensing Partnership Agreement in North America, and First in California
Feb 21, 2023 07:51AM Awakn Life Sciences Signs Its First Licensing Partnership Agreement in Europe
Feb 14, 2023 07:30AM Awakn Life Sciences Announces the Opening of Its Fourth Clinic
Feb 9, 2023 07:30AM Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology
Feb 8, 2023 06:30PM Awakn Life Sciences Responds to OTC Markets Request on Recent Promotional Activity
Feb 7, 2023 07:30AM Awakn Life Sciences Granted Fast-Track Designation from UK Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder
Jan 24, 2023 07:30AM Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect
Dec 15, 2022 07:30AM Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth
Dec 13, 2022 07:30AM Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS)
Dec 1, 2022 07:30AM Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway
Nov 23, 2022 07:30AM Awakn Life Sciences Announces Location for Larger Oslo Clinic
Nov 17, 2022 07:30AM Awakn Life Sciences Announces Closing of Private Placement
Nov 9, 2022 07:30AM Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
Oct 25, 2022 07:30AM Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations
Sep 15, 2022 07:30AM Awakn Life Sciences Reports Strong Q2 2022 Results
Sep 12, 2022 07:30AM Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Progr
Aug 25, 2022 07:30AM Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
Aug 18, 2022 07:45AM Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
View Older Stories